Verismo Therapeutics, a clinical-stage CAR T company developing a novel KIR-CAR platform technology, announced the successful manufacture of its first clinical cell product using lentiviral vector supplied by Miltenyi Bioindustry, a dedicated CDMO division of Miltenyi Biotec. The batch was produced for STAR-101, a Phase 1 clinical trial evaluating Verismo's lead pipeline SynKIR™-110 targeting mesothelin. This marks a major milestone in the clinical trial and lays the groundwork for later-stage development of SynKIR™-110 for the treatment of solid tumors.
This collaboration ensures a reliable supply chain and is an important step in preparation for Phase 2 and beyond, including use in commercial applications. Miltenyi Bioindustry is a leader in translating gene-edited cell therapy products into the clinic, including design, construction, and production of lentiviral vectors, from research through GMP manufacturing.
"Our collaboration with Miltenyi Bioindustry plays a key role as we scale our programs," said Dr. Bryan Kim, CEO of Verismo Therapeutics. "This partnership reflects Verismo's commitment to ensuring manufacturing continuity and Phase 2 clinical readiness."
Stefan Miltenyi, founder and CEO at Miltenyi Biotec, added: "We're proud to continue supporting Verismo's efforts with our viral vector platform. Their work in next-generation CAR T therapies reflects the innovation we strive to enable."